Somewhat Favorable Media Coverage Somewhat Unlikely to Impact Aptevo Therapeutics (APVO) Share Price
Press coverage about Aptevo Therapeutics (NASDAQ:APVO) has trended somewhat positive on Sunday, according to Accern. The research group identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.6416303872564 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Aptevo Therapeutics (APVO) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS (americanbankingnews.com)
- Aptevo Therapeutics (APVO) Earns “Overweight” Rating from Piper Jaffray Companies (americanbankingnews.com)
- Aptevo Therapeutics Reports Second Quarter 2018 Financial Results (finance.yahoo.com)
- Aptevo Therapeutics Inc (APVO) Expected to Post Quarterly Sales of $4.17 Million (americanbankingnews.com)
- Zacks: Analysts Expect Aptevo Therapeutics Inc (APVO) to Post -$0.65 EPS (americanbankingnews.com)
Shares of Aptevo Therapeutics traded up $0.33, hitting $4.83, during trading hours on Friday, Marketbeat reports. The company’s stock had a trading volume of 165,100 shares, compared to its average volume of 119,934. Aptevo Therapeutics has a 1-year low of $1.15 and a 1-year high of $6.35. The firm has a market capitalization of $101.64 million, a P/E ratio of -3.16 and a beta of 0.21. The company has a quick ratio of 4.39, a current ratio of 4.47 and a debt-to-equity ratio of 0.20.
Several brokerages recently issued reports on APVO. ValuEngine raised shares of Aptevo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Zacks Investment Research downgraded shares of Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Finally, Piper Jaffray Companies upped their price target on shares of Aptevo Therapeutics from $6.00 to $9.00 and gave the stock an “overweight” rating in a research report on Thursday, May 10th.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Further Reading: Momentum Indicator: Relative Strength Index
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.